Ecs Botanics Holdings Ltd
AASX:ECS0.01
AUD
0.00
(0.00%)
ISIN
AU0000052490
Return %
Stock
S&P 500
1Y
-37.50
14.20
3Y
-78.26
81.12
5Y
-86.49
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Nan-Maree Schoerie
- Full Time Employees
- 220
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- 23 Railway Rd Cressy WA Australia 6008
- IPO Date
- Apr 11, 1983
- Website
- ecsbotanics.com.au
- Similar Companies
- Business
- ECS Botanics Holdings Ltd (ASX:ECS) is an Australia-based medicinal cannabis cultivator and manufacturer headquartered in Murrabit West, Victoria, with operations utilizing progressive, regenerative, and organic horticultural practices powered by renewable energy sources; the company, founded in 2018, is licensed by the Therapeutic Goods Administration to produce PIC/S GMP and EU GMP certified products for domestic and international markets. It specializes as a B2B pharmaceutical manufacturer, cultivating high-quality cannabis strains including Sativa and Indica dominant varieties (18-25% THC), balanced CBD:THC ratios, and CBD-only options; these are processed into dried and trimmed flower for inhalation or medical use, or further extracted into resin for formulation into oils, capsules, and bespoke products supplied to strategic global partners. The company supplies markets in Australia, the United Kingdom, and other regions with medicinal cannabis programs, targeting pharmaceutical distributors, healthcare providers, and export partners through its subsidiaries ECS Botanics MC Pty Ltd and Flowerday Farms Pty Ltd. Recent developments include achieving positive net operating cash flow of A$140,000 in the September 2025 quarter, marking a A$1.6 million improvement from the prior period, driven by strong B2C sales via a one-year agreement with Elite Medical Solutions and the launch of the RAP brand alongside established B2B channels. In April 2025, ECS secured additional growth funding by increasing its National Australia Bank loan facility to A$5.2 million to support international launches of Terphogz cannabis products and expanded its GMP license to cover packaging, labeling, storage, and white-label manufacturing. The company reported a 50% increase in cannabis flower yields from redesigned protective crop enclosures, producing 656kg wet weight in its first harvest, and ordered nine new enclosures to boost premium dried flower output by over 200% to meet rising export and domestic demand; earlier milestones encompass a A$24 million five-year supply deal with MediCann Health (commenced 2024), resin agreements with Cannvalate and Sun Pharma, and first UK shipments to Lyphe Group.